Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05838729 · ClinicalTrials.gov registry record · Phase 1
Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer
A Phase 1 study of Head Neck Cancer and Intratumoral Injection, sponsored by Coordination Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT05838729: Recruiting Phase 1 study of Head Neck Cancer and Intratumoral Injection, sponsored by Coordination Pharmaceuticals.
NCT05838729 is a Phase 1 study of Head Neck Cancer and Intratumoral Injection that is actively recruiting participants, run by Coordination Pharmaceuticals. The registered enrollment target is 16 participants, below the 69-participant average among 7 other Head Neck Cancer trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05838729, a Phase 1 study of Head Neck Cancer and Intratumoral Injection, is actively recruiting participants, sponsored by Coordination Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, open-label, single arm, non-randomized study of RiMO-301 with hypofractionated radiation and a PD-1 Inhibitor in patients with unresectable, recurrent or metastatic head-neck cancer.
Primary Outcome
• The dose limiting toxicities of RiMO-301 with hypofractionated X-ray radiotherapy and a PD-1 inhibitor, as assessed by CTCAEv5, will not be observed in 33% or more patients
Conditions Studied
Interventions
- DRUG RiMO-301
Study Locations (1)
Illinois
- University of Illinois at Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2023-04-03 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
What NCT05838729 shows while recruiting
NCT05838729 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 69-participant average among 7 other Head Neck Cancer trials with a reported enrollment target (77% lower).
The record links to 2 conditions, with Head Neck Cancer appearing as the primary indexed condition, and to 1 intervention - of which RiMO-301 is the first listed.
NCT05838729 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT05838729 about?
NCT05838729 is a clinical study titled "Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer". This is a prospective, open-label, single arm, non-randomized study of RiMO-301 with hypofractionated radiation and a PD-1 Inhibitor in patients with unresectable, recurrent or metastatic head-neck cancer.
What is the current status of trial NCT05838729?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2023-04-03. Estimated completion is 2026-12.
What conditions does trial NCT05838729 study?
This clinical trial studies the following conditions: Head Neck Cancer, Intratumoral Injection.
What interventions are being tested in trial NCT05838729?
The interventions under investigation include: RiMO-301 (DRUG).
Who is sponsoring clinical trial NCT05838729?
This trial is sponsored by Coordination Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05838729 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer
RECRUITING · Phase 1
-
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)
COMPLETED · Phase 1
-
RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer
COMPLETED · Phase 1
-
First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients
RECRUITING · Phase 2
-
Stereotactic MRI-guided Focused Ultrasound Mesencephalotomy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI